New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 5 #6 October 1999
State-of-the-Art in the Management of Cancer

LUNG CANCER-PART III
SMALL CELL LUNG CANCER-EPIDEMIOLOGY, TUMOR MARKERS, STAGING, PROGNOSIS, DISEASE MONITORING, AND CURRENT TREATMENT STRATEGIES

Epidemiology

Tumor Markers

Oncogenes and Tumor Suppressor Genes

Neuroendocrine Markers

Diagnosis, Staging, Prognosis and Disease Monitoring

Serum Markers

  • Neuron-specific enolase
  • Pro-gastrin-releasing peptide
  • Chromogranin A
  • Multiple serum markers

Angiogenesis Markers

Detection of Tumor Cells in Bone Marrow

Noninvasive Imaging

  • Bone scans
  • Scintigraphy
  • Positron emission tomography (PET)

Treatment of Primary SCLC

Surgery

Radiation Therapy

  • Thoracic radiation therapy (RT)
  • Prophylactic cranial irradiation (PCI)

Chemotherapy

  • Combination chemotherapy
  • Single-agent chemotherapy
  • Intensive chemotherapy/chemoradiotherapy

Management of Refractory/Relapsed SCLC

Drug Resistance in SCLC

Second-line Chemotherapy

  • Gemcitabine
  • Topotecan
  • Paclitaxel

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887